SCHEMBL6474227

SCHEMBL6474227

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 7/20 0.46
GRIA4 P48058 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MMP13 P45452 2/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
ADAMTS4 O75173 1/20 0.39
PTPN5 P54829 1/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
LMNA P02545 4/20 0.38
NPC1 O15118 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
MTOR P42345 2/20 0.38
RAB9A P51151 2/20 0.38
CYP3A4 P08684 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482324 0.90 GRIA4 (0.46) GRIA4CA2HSD17B10MMP13CYP2C19
SCHEMBL6475469 0.89 PLAU (0.43) KIF11GRIA4ALDH1A1HSD17B10MMP13
SCHEMBL6475311 0.86 GRIA4 (0.47) GRIA4CA1CA2ALDH1A1ADAMTS4
SCHEMBL6475840 0.85 CA2 (0.41) KIF11GRIA4CA2MMP13ADAMTS4
SCHEMBL6482161 0.85 MTNR1A (0.49) GRIA4HSD17B10MMP13KDM4ETP53
SCHEMBL6475297 0.85 GRIA4 (0.48) GRIA4ALDH1A1MMP13NPC1CYP2C19
SCHEMBL6474393 0.85 GRIA4 (0.43) GRIA4CA2ALDH1A1HSD17B10MEN1
SCHEMBL6472661 0.84 GRIA4 (0.42) KIF11GRIA4CA1CA2SIGMAR1
SCHEMBL6474222 0.84 KIF11 (0.44) KIF11GRIA4CA1CA2MMP13
SCHEMBL6480923 0.83 GRIA4 (0.51) GRIA4MMP13ADAMTS4MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 KIF11 4340/4885GRIA4 6/4885CA1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.